
Adults with AChR antibody–positive generalized myasthenia gravis now have a C5 inhibitor they can inject themselves at home once a week.
Kovaltry temporarily replaces the missing clotting Factor VIII in patients with hemophilia A.
Medication Pearl of the Day: Kovaltry (Antihemophilic Factor)
Indication: Kovaltry Antihemophilic Factor (Recombinant), is a recombinant, human DNA sequence-derived, full length Factor VIII concentrate indicated for use in adults and children with hemophilia A.
Insight:
Sources:






